The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer
Abstract Background Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta‐analysis...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2462 |
| _version_ | 1819118477830520832 |
|---|---|
| author | Xiaoshun Shi Xiaoying Dong Sylvia Young Allen Menglin Chen Xiguang Liu Zhouxia Zheng Kailing Huang Di Lu Siyang Feng Grant Morahan Kaican Cai |
| author_facet | Xiaoshun Shi Xiaoying Dong Sylvia Young Allen Menglin Chen Xiguang Liu Zhouxia Zheng Kailing Huang Di Lu Siyang Feng Grant Morahan Kaican Cai |
| author_sort | Xiaoshun Shi |
| collection | DOAJ |
| description | Abstract Background Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta‐analysis. Methods The impact of five angiogenesis inhibitors, that is, vandetanib (Van), bevacizumab (Bev), Rh‐endostatin (End), sunitinib (Sun), and thalidomide (Tha), on progression‐free survival (PFS) and overall survival (OS) was evaluated by conducting a network meta‐analysis. RNA sequencing data were downloaded from publicly available databases. Results Nine phase II and III randomized controlled trials (RCTs), that involved 1599 participants, that investigated angiogenesis inhibitors in the treatment of SCLC were included in this meta‐analysis. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR = 0.88, 95% CI: 0.79‐0.98, Sun VS. Tha, HR = 0.80, 95% CI: 0.65‐1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR = 0.89, 95%CI: 0.81‐0.97, Sun VS. Placebo, HR = 0.81, 95% CI: 0.66‐1.00). Based on this study, we found no significant difference of OS of SCLC. The angiogenesis pathway and expression of target genes were globally deactivated in SCLC tissue. Conclusion Results of this network meta‐analysis indicate that the PFS outcome of SCLC with Sun or Bev drugs is superior to that of Tha. The improved therapeutic impact of angiogenesis inhibitors on SCLC needs more evidence, such as long‐term observation in clinical trials, to be validated. |
| first_indexed | 2024-12-22T05:49:30Z |
| format | Article |
| id | doaj.art-1dc1d0d696494cc89087bf4bc24459e6 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-22T05:49:30Z |
| publishDate | 2019-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-1dc1d0d696494cc89087bf4bc24459e62022-12-21T18:36:55ZengWileyCancer Medicine2045-76342019-10-018135930593810.1002/cam4.2462The impact of angiogenesis inhibitors on survival of patients with small cell lung cancerXiaoshun Shi0Xiaoying Dong1Sylvia Young2Allen Menglin Chen3Xiguang Liu4Zhouxia Zheng5Kailing Huang6Di Lu7Siyang Feng8Grant Morahan9Kaican Cai10Department of Thoracic Surgery, Nanfang Hospital Southern Medical University Guangzhou P. R. ChinaDepartment of Thoracic Surgery, Nanfang Hospital Southern Medical University Guangzhou P. R. ChinaHarry Perkins Institute of Medical Research, Centre for Medical Research University of Western Australia Nedlands WA AustraliaMendel Genes Inc Guangzhou ChinaDepartment of Thoracic Surgery, Nanfang Hospital Southern Medical University Guangzhou P. R. ChinaMendel Genes Inc Guangzhou ChinaMendel Genes Inc Guangzhou ChinaDepartment of Thoracic Surgery, Nanfang Hospital Southern Medical University Guangzhou P. R. ChinaDepartment of Thoracic Surgery, Nanfang Hospital Southern Medical University Guangzhou P. R. ChinaHarry Perkins Institute of Medical Research, Centre for Medical Research University of Western Australia Nedlands WA AustraliaDepartment of Thoracic Surgery, Nanfang Hospital Southern Medical University Guangzhou P. R. ChinaAbstract Background Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta‐analysis. Methods The impact of five angiogenesis inhibitors, that is, vandetanib (Van), bevacizumab (Bev), Rh‐endostatin (End), sunitinib (Sun), and thalidomide (Tha), on progression‐free survival (PFS) and overall survival (OS) was evaluated by conducting a network meta‐analysis. RNA sequencing data were downloaded from publicly available databases. Results Nine phase II and III randomized controlled trials (RCTs), that involved 1599 participants, that investigated angiogenesis inhibitors in the treatment of SCLC were included in this meta‐analysis. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR = 0.88, 95% CI: 0.79‐0.98, Sun VS. Tha, HR = 0.80, 95% CI: 0.65‐1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR = 0.89, 95%CI: 0.81‐0.97, Sun VS. Placebo, HR = 0.81, 95% CI: 0.66‐1.00). Based on this study, we found no significant difference of OS of SCLC. The angiogenesis pathway and expression of target genes were globally deactivated in SCLC tissue. Conclusion Results of this network meta‐analysis indicate that the PFS outcome of SCLC with Sun or Bev drugs is superior to that of Tha. The improved therapeutic impact of angiogenesis inhibitors on SCLC needs more evidence, such as long‐term observation in clinical trials, to be validated.https://doi.org/10.1002/cam4.2462angiogenesis inhibitorsnetwork meta‐analysisrandomized controlled trialsmall cell lung cancertarget drugs |
| spellingShingle | Xiaoshun Shi Xiaoying Dong Sylvia Young Allen Menglin Chen Xiguang Liu Zhouxia Zheng Kailing Huang Di Lu Siyang Feng Grant Morahan Kaican Cai The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer Cancer Medicine angiogenesis inhibitors network meta‐analysis randomized controlled trial small cell lung cancer target drugs |
| title | The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer |
| title_full | The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer |
| title_fullStr | The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer |
| title_full_unstemmed | The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer |
| title_short | The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer |
| title_sort | impact of angiogenesis inhibitors on survival of patients with small cell lung cancer |
| topic | angiogenesis inhibitors network meta‐analysis randomized controlled trial small cell lung cancer target drugs |
| url | https://doi.org/10.1002/cam4.2462 |
| work_keys_str_mv | AT xiaoshunshi theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT xiaoyingdong theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT sylviayoung theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT allenmenglinchen theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT xiguangliu theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT zhouxiazheng theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT kailinghuang theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT dilu theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT siyangfeng theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT grantmorahan theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT kaicancai theimpactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT xiaoshunshi impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT xiaoyingdong impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT sylviayoung impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT allenmenglinchen impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT xiguangliu impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT zhouxiazheng impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT kailinghuang impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT dilu impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT siyangfeng impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT grantmorahan impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer AT kaicancai impactofangiogenesisinhibitorsonsurvivalofpatientswithsmallcelllungcancer |